Literature DB >> 29581074

Antimicrobial susceptibility profiles of bacteria causing urinary tract infections in Mexico: Single-centre experience with 10 years of results.

Francisco Alejandro Lagunas-Rangel1.   

Abstract

OBJECTIVES: The aim of this retrospective study was to describe urinary tract infections (UTIs) diagnosed in a single centre in Mexico through 10 years of results, with a particular emphasis on the aetiology, patterns of antimicrobial susceptibility and incidence of extended-spectrum β-lactamase (ESBL)-producing strains.
METHODS: This study involved all urine samples analysed during the period March 2007 to September 2017 in a single centre in Mexico. Isolated uropathogens were identified to species level using routine laboratory methods, and antimicrobial susceptibility was determined by the disk diffusion method.
RESULTS: Overall, 859 urinary isolates were identified, including 582 (67.8%) Escherichia coli, 69 (8.0%) Enterococcus faecalis, 29 (3.4%) Klebsiella pneumoniae, 24 (2.8%) Proteus mirabilis, 24 (2.8%) Pseudomonas aeruginosa, 23 (2.7%) Candida albicans, 18 (2.1%) Streptococcus agalactiae and 10 (1.2%) Candida glabrata. Patient sex and age were the main risk factors associated with UTI in this population. Nitrofurantoin together with fosfomycin and amikacin had the highest percentages of susceptibility. Of the 859 isolates, 213 (24.8%) presented a positive double-disk synergy test indicating the presence of an ESBL phenotype, with E. coli showing a gradual increase in ESBL-producing isolates over time.
CONCLUSIONS: These results provide additional evidence in relation to the role of different bacterial species as aetiological agents of UTI as well as antimicrobial susceptibility information that will help to guide the selection of antimicrobial treatment for UTIs and the prevalence of ESBL-producing strains over a 10-year period in a Mexican centre.
Copyright © 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobials; ESBL; Escherichia coli; Extended-spectrum β-lactamase; Resistance; Urine culture

Mesh:

Substances:

Year:  2018        PMID: 29581074     DOI: 10.1016/j.jgar.2018.03.004

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  6 in total

1.  Novel 5-Nitrofuran-Activating Reductase in Escherichia coli.

Authors:  Vuong Van Hung Le; Ieuan G Davies; Christina D Moon; David Wheeler; Patrick J Biggs; Jasna Rakonjac
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Clinical isolates of Escherichia coli are resistant both to antibiotics and organotin compounds.

Authors:  M Aguilar-Santelises; J Castillo-Vera; R Gonzalez-Molina; A Garcia Del Valle; M Cruz Millan; L Aguilar-Santelises
Journal:  Folia Microbiol (Praha)       Date:  2019-04-17       Impact factor: 2.099

3.  Characterization of commercial poultry farms in Mexico: Towards a better understanding of biosecurity practices and antibiotic usage patterns.

Authors:  Erika Ornelas-Eusebio; Gary García-Espinosa; Karine Laroucau; Gina Zanella
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

4.  Prevalence and Antibiotic Susceptibility of the Common Bacterial Uropathogen Among UTI Patients in French Medical Institute for Children.

Authors:  Mahdawi Joya; Ahmad Khalid Aalemi; Abdul Tawab Baryali
Journal:  Infect Drug Resist       Date:  2022-08-06       Impact factor: 4.177

5.  Efficacy of Fosfomycin against Planktonic and Biofilm-Associated MDR Uropathogenic Escherichia coli Clinical Isolates.

Authors:  Haziel Eleazar Dzib-Baak; Andrés Humberto Uc-Cachón; Angel de Jesús Dzul-Beh; Rey Fernando Rosado-Manzano; Carlos Gracida-Osorno; Gloria María Molina-Salinas
Journal:  Trop Med Infect Dis       Date:  2022-09-08

6.  Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system.

Authors:  Eva Raphael; M Maria Glymour; Henry F Chambers
Journal:  Antimicrob Resist Infect Control       Date:  2021-08-11       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.